Vcap prostate cancer cells

LNCaP (clone FGC), PC-3, and VCaP prostate cancer cells were purchased from American Type Culture Collection. The MR49F cell line was a kind gift from Dr Martin Gleave (Vancouver Prostate Center, Vancouver, BC). All cells were maintained at 37°C in a humidified atmosphere containing 5% CO₂. LNCaP and PC-3 cells were cultured in the Roswell Park Memorial Institute-1640 (RPMI-1640) media supplemented with 10% fetal bovine serum (FBS) and VCaP cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) media supplemented with 10% FBS. The enzalutamide-resistant derivative of the LNCaP cell line, MR49F, was cultured in RPMI-1640 media supplemented with 10% FBS and 10 μM MDV3100.^{30 (link)} MDV3100 was purchased from SelleckChem (S1250; Houston, TX). All cell lines used were authenticated by short tandem repeat analyses at the Johns Hopkins Genetic Resources Core Facility. BMPC-1 cells were as in Markowski et al^{31 (link)} and were cultured in DMEM supplemented with 10% FBS.
BMH-21 was synthesized at the Drug Discovery Division, Lieber Institute (Baltimore, MD), and the chemical structure and purity were verified using liquid chromatography-mass spectrometry and proton nuclear magnetic resonance.